AstraZeneca's Tagrisso gains EU approval for lung cancer treatment

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Today's news reinforces Tagrisso as the backbone therapy in EGFR- ...

CHMP recommends AstraZeneca's Tagrisso for EU approval

EMA's CHMP has recommended AstraZeneca's Tagrisso for approval in the European Union to treat individuals with NSCLC.

AstraZeneca's Tagrisso Gains EU Approval Nod - TipRanks.com

AstraZeneca (GB:AZN) has released an update. AstraZeneca's Tagrisso has been recommended for approval in the EU for treating advanced, ...

Tagrisso with the addition of chemotherapy approved in the EU as ...

As part of AstraZeneca's ongoing commitment to treating patients as early as possible in lung cancer, Tagrisso is also being investigated in the ...

AstraZeneca's Tagrisso Gains EU Approval Nod | Markets Insider

Don't Miss our Black Friday Offers: ... AstraZeneca's Tagrisso has been recommended for approval in the EU for treating advanced, unresectable ...

AstraZeneca's Tagrisso gains EU approval for lung cancer treatment

AstraZeneca has announced that the EU's European Commission (EC) has approved Tagrisso (osimertinib), with the addition of pemetrexed and ...

Osimertinib Plus Chemotherapy Gains European Approval for ...

The European Union (EU) has approved osimertinib (Tagrisso) in combination with chemotherapy as a first-line treatment for patients with ...

CHMP recommends AstraZeneca's Tagrisso for EU approval for ...

“Tagrisso has now demonstrated its benefit across all stages of EGFR-mutated lung cancer, representing a pivotal step in transforming care for ...

FDA expands label for AZ's Tagrisso in key NSCLC indication

The FDA has signed off on Tagrisso to become the first targeted therapy for unresectable, stage 3 EGFRm non-small cell lung cancer.

AstraZeneca's Tagrisso plus chemotherapy wins EU approval for ...

AstraZeneca has won approval from the European Commission for Tagrisso (osimertinib) in combination with chemotherapy for non-small cell lung cancer (NSCLC) ...

FDA Approves Osimertinib in Stage III NSCLC

... osimertinib (Tagrisso; AstraZeneca) for adult patients who have ... Osimertinib with chemo gains FDA approval for EGFR-mutated NSCLC.

AstraZeneca Plc Tagrisso recommended for approval in the EU for ...

AstraZeneca's Tagrisso recommended EU approval for 1st-line treatment of EGFRm NSCLC with positive results from FLAURA2 trial published in ...

Treatment for Certain Types of EGFR+ NSCLC | TAGRISSO ...

TAGRISSO is approved to treat certain types of EGFR+ non-small cell lung cancer (NSCLC) · more time without their cancer growing or spreading.

AstraZeneca's Tagrisso plus chemotherapy wins EU approval for ...

AstraZeneca's Tagrisso plus chemotherapy wins EU approval for NSCLC. Pharmaceutical Technology · rarrarorro via Shutterstock. Jenna Philpott.

Astrazeneca Gets European Approval for Its New Lung Cancer Drug

European regulators have given the green light to Astrazeneca's new lung cancer drug Tagrisso, a potential blockbuster treatment.

AstraZeneca hails recommended EU approval of Tagrisso

AstraZeneca PLC on Monday said that the EU's Committee for Medicinal Products for Human Use, or CHMP, recommended its cancer drug Tagrisso ...

FDA Approves AstraZeneca's Tagrisso Plus Chemotherapy for ...

This approval reinforces Tagrisso as the backbone of EGFR-mutated lung cancer treatment either as monotherapy or in combination with ...

EU approves AstraZeneca's Tagrisso combined with chemotherapy ...

The European Commission has approved AstraZeneca's Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy for ...

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: “Today's news reinforces Tagrisso as the backbone therapy in EGFR- ...

AstraZeneca's cell lung cancer drug sent for EU approval

AstraZeneca Plc.'s treatment for patients with unresectable non-small cell lung cancer Tagrisso gained key recommendation for approval in ...